Reza Dana

List of Publications by Year
in descending order

260 papers	20,078 citations	23500 58 h-index	16127 124 g-index
266 all docs	266 docs citations	266 times ranked	14819 citing authors

#	Article	IF	Citations
1	Development and characterization of a hydrogel-based adhesive patch for sealing open-globe injuries. Acta Biomaterialia, 2022, 137, 53-63.	4.1	27
2	The Neuropeptide Alpha-Melanocyteâ€“Stimulating Hormone Is Critical for Corneal Endothelial Cell Protection and Graft Survival after Transplantation. American Journal of Pathology, 2022, 192, 270-280.	1.9	7
3	Bevacizumab in High-Risk Corneal Transplantation. Ophthalmology, 2022, 129, 865-879.	2.5	6
4	Autoreactive memory Th17Âcells are principally derived from T-bet+RORÎ³t+ Th17/1 effectors. Journal of Autoimmunity, 2022, 129, 102816.	3.0	6
5	Immune regulation of the ocular surface. Experimental Eye Research, 2022, 218, 109007.	1.2	17
6	DryEyeRhythm: A reliable and valid smartphone application for the diagnosis assistance of dry eye. Ocular Surface, 2022, 25, 19-25.	2.2	20
7	A Novel Murine Model of Endothelial Keratoplasty. Cornea, 2022, Publish Ahead of Print, .	0.9	1
8	Impact of aging on the pathophysiology of dry eye disease: A systematic review and meta-analysis. Ocular Surface, 2022, 25, 108-118.	2.2	22
9	Neurotrophic Keratopathy in the United States. Ophthalmology, 2022, 129, 1255-1262.	2.5	14
10	Prevalence of neurotrophic keratopathy in patients with chronic ocular graft-versus-host disease. Ocular Surface, 2022, 26, 13-18.	2.2	5
11	Modulating the tachykinin: Role of substance P and neurokinin receptor expression in ocular surface disorders. Ocular Surface, 2022, 25, 142-153.	2.2	13
12	The functions of IL-23 and IL-2 on driving autoimmune effector T-helper 17 cells into the memory pool in dry eye disease. Mucosal Immunology, 2021, 14, 177-186.	2.7	13
13	The role of Th17 immunity in chronic ocular surface disorders. Ocular Surface, 2021, 19, 157-168.	2.2	26
14	Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. The Lancet Global Health, 2021, 9, e130-e143.	2.9	500
15	Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet Global Health, 2021, 9, e144-e160.	2.9	1,148
16	Growth factor-eluting hydrogels for management of corneal defects. Materials Science and Engineering C, 2021, 120, 111790.	3.8	6
17	Heterogeneity of eye drop use among symptomatic dry eye individuals in Japan: large-scale crowdsourced research using DryEyeRhythm application. Japanese Journal of Ophthalmology, 2021, 65, 271-281.	0.9	21
18	Dry Eye Diagnosis and Management. , 2021, , 1-28.		0

#	Article	IF	Citations
19	Advances in the Medical Management of Neurotrophic Keratitis. Seminars in Ophthalmology, 2021, 36, 335-340.	0.8	10
20	Corneal angiogenic privilege and its failure. Experimental Eye Research, 2021, 204, 108457.	1.2	25
21	Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey. BMJ Open, 2021, 11, e039209.	0.8	16
22	Pigment Epitheliumâ€“Derived Factor Enhances the Suppressive Phenotype of Regulatory T Cells in a Murine Model of Dry Eye Disease. American Journal of Pathology, 2021, 191, 720-729.	1.9	7
23	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer Journal, 2021, 11, 103.	2.8	32
24	Advanced nanodelivery platforms for topical ophthalmic drug delivery. Drug Discovery Today, 2021, 26, 1437-1449.	3.2	30
25	Chemical and thermal ocular burns in the United States: An IRIS registry analysis. Ocular Surface, 2021, 21, 345-347.	2.2	7
26	Ocular redness â€“ II: Progress in development of therapeutics for the management of conjunctival hyperemia. Ocular Surface, 2021, 21, 66-77.	2.2	7
27	A Review of Ocular Graft-versus-Host Disease: Pathophysiology, Clinical Presentation and Management. Ocular Immunology and Inflammation, 2021, 29, 1190-1199.	1.0	24
28	Ocular redness â€“ I: Etiology, pathogenesis, and assessment of conjunctival hyperemia. Ocular Surface, 2021, 21, 134-144.	2.2	23
29	Preclinical Evaluation of the Safety and Efficacy of Cryopreserved Bone Marrow Mesenchymal Stromal Cells for Corneal Repair. Translational Vision Science and Technology, 2021, 10, 3.	1.1	11
30	Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy. BMC Ophthalmology, 2021, 21, 327.	0.6	15
31	Autoimmunity in dry eye disease â€“ An updated review of evidence on effector and memory Th17 cells in disease pathogenicity. Autoimmunity Reviews, 2021, 20, 102933.	2.5	30
32	Dry eye disease flares: A rapid evidence assessment. Ocular Surface, 2021, 22, 51-59.	2.2	9
33	Corneal lymphangiogenesis in dry eye disease is regulated by substance P/neurokinin-1 receptor system through controlling expression of vascular endothelial growth factor receptor 3. Ocular Surface, 2021, 22, 72-79.	2.2	16
34	Long-term Outcomes of Punctal Cauterization in the Management of Ocular Surface Diseases. Cornea, 2021, 40, 168-171.	0.9	11
35	Prevalence and Risk Factors Associated With Corneal Perforation in Chronic Ocular Graft-Versus-Host-Disease. Cornea, 2021, 40, 877-882.	0.9	9
36	Smartphone-based digital phenotyping for dry eye toward P4 medicine: a crowdsourced cross-sectional study. Npj Digital Medicine, 2021, 4, 171.	5.7	30

#	Article	IF	Citations
37	Novel adaptation of a running suture technique in a mouse model of corneal transplantation.. Journal of Biological Methods, 2021, 8, e156.	1.0	1
38	Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy. Ophthalmology, 2020, 127, 14-26.	2.5	150
39	Management of meibomian gland dysfunction: a review. Survey of Ophthalmology, 2020, 65, 205-217.	1.7	111
40	Neurokinin-1 Receptor Antagonism Ameliorates Dry Eye Disease by Inhibiting Antigen-Presenting Cell Maturation and T Helper 17 Cell Activation. American Journal of Pathology, 2020, 190, 125-133.	1.9	34
41	Regulatory T cells promote corneal endothelial cell survival following transplantation via interleukin-10. American Journal of Transplantation, 2020, 20, 389-398.	2.6	12
42	Letter From the New Editor-in-Chief. Cornea, 2020, 39, 1-1.	0.9	2
43	Characteristics and Risk Factors Associated With Diagnosed and Undiagnosed Symptomatic Dry Eye Using a Smartphone Application. JAMA Ophthalmology, 2020, 138, 58.	1.4	65
44	Efficacy of cyanoacrylate tissue adhesive in the management of corneal thinning and perforation due to microbial keratitis. Ocular Surface, 2020, 18, 795-800.	2.2	15
45	Global Consensus on the Management of Limbal Stem Cell Deficiency. Cornea, 2020, 39, 1291-1302.	0.9	74
46	Association of Î±-Melanocyteâ€“Stimulating Hormone With Corneal Endothelial Cell Survival During Oxidative Stress and Inflammation-Induced Cell Loss in Donor Tissue. JAMA Ophthalmology, 2020, 138, 1192.	1.4	9
47	Regulatory T Cells in Angiogenesis. Journal of Immunology, 2020, 205, 2557-2565.	0.4	39
48	Prevalence of Persistent Corneal Epithelial Defects in Chronic Ocular Graft-Versus-Host Disease. American Journal of Ophthalmology, 2020, 218, 296-303.	1.7	19
49	Ciprofloxacin-loaded bioadhesive hydrogels for ocular applications. Biomaterials Science, 2020, 8, 5196-5209.	2.6	44
50	Advances and limitations of drug delivery systems formulated as eye drops. Journal of Controlled Release, 2020, 321, 1-22.	4.8	175
51	Animal models of high-risk corneal transplantation: A comprehensive review. Experimental Eye Research, 2020, 198, 108152.	1.2	10
52	Efficacy and retention of silicone punctal plugs for treatment of dry eye in patients with and without ocular graft-versus-host-disease. Ocular Surface, 2020, 18, 731-735.	2.2	11
53	Clinical and Prodromal Ocular Symptoms in Coronavirus Disease: A Systematic Review and Meta-Analysis. , 2020, 61, 29.		51
54	Defining Dry Eye from a Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 9271.	1.8	118

#	Article	IF	Citations
55	Pigment Epithelium-derived Factor secreted by corneal epithelial cells regulates dendritic cell maturation in dry eye disease. Ocular Surface, 2020, 18, 460-469.	2.2	19
56	Restoration of Regulatory T-Cell Function in Dry Eye Disease by Antagonizing Substance P/Neurokinin-1 Receptor. American Journal of Pathology, 2020, 190, 1859-1866.	1.9	25
57	Sensory neurons directly promote angiogenesis in response to inflammation via substance P signaling. FASEB Journal, 2020, 34, 6229-6243.	0.2	36
58	Association between dry eye and depressive symptoms: Large-scale crowdsourced research using the DryEyeRhythm iPhone application. Ocular Surface, 2020, 18, 312-319.	2.2	44
59	Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey. American Journal of Ophthalmology, 2020, 216, 7-17.	1.7	33
60	Aged Mice Exhibit Severe Exacerbations of Dry Eye Disease with an Amplified Memory Th17 Cell Response. American Journal of Pathology, 2020, 190, 1474-1482.	1.9	20
61	Pathophysiology of Corneal Graft Rejection. , 2020, , 87-96.		2
62	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 26-27.	0.6	6
63	Stratification of Individual Symptoms of Contact Lensâ€“Associated Dry Eye Using the iPhone App DryEyeRhythm: Crowdsourced Cross-Sectional Study. Journal of Medical Internet Research, 2020, 22, e18996.	2.1	27
64	Immune checkpoint inhibitors and corneal transplant rejection: aÂcall for awareness. Immunotherapy, 2020, 12, 947-949.	1.0	5
65	Future Directions in theÂField of Cornea. , 2020, , 381-388.		0
66	Keratoconus progression associated with hormone replacement therapy. American Journal of Ophthalmology Case Reports, 2019, 15, 100519.	0.4	19
67	The purinergic receptor antagonist oxidized adenosine triphosphate suppresses immune-mediated corneal allograft rejection. Scientific Reports, 2019, 9, 8617.	1.6	5
68	Conjunctival HLA-DR Expression and Its Association With Symptoms and Signs in the DREAM Study. Translational Vision Science and Technology, 2019, 8, 31.	1.1	7
69	Descemet Membrane Endothelial Keratoplasty Failure Associated with Innate Immune Activation. Ophthalmology, 2019, 126, 1462-1464.	2.5	10
70	Thrombospondin-1 in ocular surface health and disease. Ocular Surface, 2019, 17, 374-383.	2.2	27
71	Methods for Assessing Corneal Opacity. Seminars in Ophthalmology, 2019, 34, 205-210.	0.8	15
72	Medical and surgical management of conjunctivochalasis. Ocular Surface, 2019, 17, 393-399.	2.2	15

#	Article	IF	Citations
73	Retinal microglia initiate neuroinflammation in ocular autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9989-9998.	3.3	104
74	Sutureless repair of corneal injuries using naturally derived bioadhesive hydrogels. Science Advances, 2019, 5, eaav1281.	4.7	229
75	Oral guaifenesin for treatment of filamentary keratitis: A pilot study. Ocular Surface, 2019, 17, 565-570.	2.2	2
76	InÂVivo Confocal Microscopy Demonstrates Increased Immune Cell Densities in Corneal Graft Rejection Correlating With Signs and Symptoms. American Journal of Ophthalmology, 2019, 203, 26-36.	1.7	13
77	Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. American Journal of Ophthalmology, 2019, 202, 47-54.	1.7	139
78	Global Consensus on Definition, Classification, Diagnosis, and Staging of Limbal Stem Cell Deficiency. Cornea, 2019, 38, 364-375.	0.9	196
79	Dry eye disease ranking among common reasons for seeking eye care in a large US claims database . Clinical Ophthalmology, 2019, Volume 13, 225-232.	0.9	38
80	Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases. Journal of Immunology, 2019, 203, 2749-2755.	0.4	82
81	Outcomes of Cyanoacrylate Tissue Adhesive Application in Corneal Thinning and Perforation. Cornea, 2019, 38, 668-673.	0.9	44
82	Reply. Cornea, 2019, 38, e56-e57.	0.9	0
83	Local Delivery of Regulatory T Cells Promotes Corneal Allograft Survival. Transplantation, 2019, 103, 182-190.	0.5	24
84	Impact of Dry Eye on Visual Acuity and Contrast Sensitivity: Dry Eye Assessment and Management Study. Optometry and Vision Science, 2019, 96, 387-396.	0.6	37
85	Limbal and Conjunctival Epithelial Thickness in Ocular Graft-Versus-Host Disease. Cornea, 2019, 38, 1286-1290.	0.9	3
86	Risk Factors for Severe Dry Eye Disease: Crowdsourced Research Using DryEyeRhythm. Ophthalmology, 2019, 126, 766-768.	2.5	45
87	Ocular adhesives: Design, chemistry, crosslinking mechanisms, and applications. Biomaterials, 2019, 197, 345-367.	5.7	84
88	Microglia Regulate Neuroglia Remodeling in Various Ocular and Retinal Injuries. Journal of Immunology, 2019, 202, 539-549.	0.4	36
89	Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study. American Journal of Ophthalmology, 2019, 198, 181-192.	1.7	16
90	A standardized methodology for longitudinal assessment of corneal endothelial morphometry in eye banked corneas. Journal of Biological Methods, 2019, 6, e120.	1.0	3

#	Article	IF	Citations
91	The Role of Microglia and Peripheral Monocytes in Retinal Damage after Corneal Chemical Injury. American Journal of Pathology, 2018, 188, 1580-1596.	1.9	54
92	Meibomian Gland Dysfunction in Primary and Secondary SjÃ¶gren Syndrome. Ophthalmic Research, 2018, 59, 193-205.	1.0	47
93	Web-based longitudinal remote assessment of dry eye symptoms. Ocular Surface, 2018, 16, 249-253.	2.2	17
94	Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function. Stem Cells, 2018, 36, 775-784.	1.4	49
95	Therapeutic approaches for induction of tolerance and immune quiescence in corneal allotransplantation. Cellular and Molecular Life Sciences, 2018, 75, 1509-1520.	2.4	15
96	Factors Influencing the Diagnostic Accuracy of Laser-Scanning In Vivo Confocal Microscopy for Acanthamoeba Keratitis. Cornea, 2018, 37, 818-823.	0.9	22
97	A New Frontier in Curing Corneal Blindness. New England Journal of Medicine, 2018, 378, 1057-1058.	13.9	10
98	Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease. American Journal of Ophthalmology, 2018, 190, 17-23.	1.7	18
99	Subtarsal Fibrosis Is Associated With Ocular Surface Epitheliopathy in Graft-Versus-Host Disease. American Journal of Ophthalmology, 2018, 189, 102-110.	1.7	27
100	Corneal Tissue From Dry Eye Donors Leads to Enhanced Graft Rejection. Cornea, 2018, 37, 95-101.	0.9	24
101	When Clarity Is Crucial: Regulating Ocular Surface Immunity. Trends in Immunology, 2018, 39, 288-301.	2.9	54
102	Conjunctivochalasis: a systematic review. Survey of Ophthalmology, 2018, 63, 554-564.	1.7	32
103	Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities. Cornea, 2018, 37, 248-251.	0.9	34
104	Permanent neuroglial remodeling of the retina following infiltration of CSF1R inhibition-resistant peripheral monocytes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11359-E11368.	3.3	50
105	Regulatory T Cell Modulation of Cytokine and Cellular Networks in Corneal Graft Rejection. Current Ophthalmology Reports, 2018, 6, 266-274.	0.5	16
106	Corneal fluorescein staining and ocular symptoms but not Schirmer test are useful as indicators of response to treatment in chronic ocular GVHD. Ocular Surface, 2018, 16, 377-381.	2.2	15
107	The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease. Ocular Surface, 2018, 16, 470-477.	2.2	29
108	Pathological conversion of regulatory T cells is associated with loss of allotolerance. Scientific Reports, 2018, 8, 7059.	1.6	77

#	Article	IF	Citations
109	Vasoactive Intestinal Peptide Promotes Corneal Allograft Survival. American Journal of Pathology, 2018, 188, 2016-2024.	1.9	25
110	Interleukin-6 neutralization prolongs corneal allograft survival. Current Trends in Immunology, 2018, 19, 105-113.	4.0	2
111	Regulatory T cell modulation of cytokine and cellular networks in corneal graft rejection. Current Ophthalmology Reports, 2018, 6, 266-274.	0.5	10
112	Exophiala phaeomuriformis Fungal Keratitis: Case Report and In Vivo Confocal Microscopy Findings. Eye and Contact Lens, 2017, 43, e4-e6.	0.8	15
113	Elevated Neutrophil Elastase in Tears of Ocular Graft-Versus-Host Disease Patients. American Journal of Ophthalmology, 2017, 176, 46-52.	1.7	39
114	Ageing and ocular surface immunity. British Journal of Ophthalmology, 2017, 101, 1-5.	2.1	28
115	Optimising keratoplasty for Peters' anomaly in infants using spectral-domain optical coherence tomography. British Journal of Ophthalmology, 2017, 101, 820-827.	2.1	12
116	Mechanisms of Retinal Damage after Ocular Alkali Burns. American Journal of Pathology, 2017, 187, 1327-1342.	1.9	59
117	Treatment of donor corneal tissue with immunomodulatory cytokines: a novel strategy to promote graft survival in high-risk corneal transplantation. Scientific Reports, 2017, 7, 971.	1.6	28
118	Kinetics of Angiogenic Responses in Corneal Transplantation. Cornea, 2017, 36, 491-496.	0.9	38
119	A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease. Cornea, 2017, 36, 799-804.	0.9	26
120	Sensitivity and Specificity of Laser-Scanning InÂVivo Confocal Microscopy for Filamentous Fungal Keratitis: Role of Observer Experience. American Journal of Ophthalmology, 2017, 179, 81-89.	1.7	43
121	Interleukin-7 and -15 maintain pathogenic memory Th17 cells in autoimmunity. Journal of Autoimmunity, 2017, 77, 96-103.	3.0	43
122	Determinants of Ocular Pain Severity in Patients With Dry Eye Disease. American Journal of Ophthalmology, 2017, 179, 198-204.	1.7	25
123	Proangiogenic Function of T Cells in Corneal Transplantation. Transplantation, 2017, 101, 778-785.	0.5	23
124	IFN-Î³â€“Expressing Th17 Cells Are Required for Development of Severe Ocular Surface Autoimmunity. Journal of Immunology, 2017, 199, 1163-1169.	0.4	70
125	Patients' Perceived Treatment Effectiveness in Dry Eye Disease. Cornea, 2017, 36, 893-897.	0.9	6
126	Review: The function of regulatory T cells at the ocular surface. Ocular Surface, 2017, 15, 652-659.	2.2	26

#	Article	IF	Citations
127	Management of high-risk corneal transplantation. Survey of Ophthalmology, 2017, 62, 816-827.	1.7	102
128	Global causes of blindness and distance vision impairment 1990â€“2020: a systematic review and meta-analysis. The Lancet Global Health, 2017, 5, e1221-e1234.	2.9	2,053
129	TFOS DEWS II Management and Therapy Report. Ocular Surface, 2017, 15, 575-628.	2.2	839
130	Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. The Lancet Global Health, 2017, 5, e888-e897.	2.9	1,443
131	Patients With Dry Eye Disease and Low Subbasal Nerve Density Are at High Risk for Accelerated Corneal Endothelial Cell Loss. Cornea, 2017, 36, 196-201.	0.9	35
132	Infliximab after Boston Keratoprosthesis in Stevensâ€“Johnson Syndrome: An Update. Ocular Immunology and Inflammation, 2017, 25, 413-417.	1.0	22
133	Kinetics of Corneal Antigen Presenting Cells in Experimental Dry Eye Disease. BMJ Open Ophthalmology, 2017, 1, e000078.	0.8	33
134	Evaluating Corneal Fluorescein Staining Using a Novel Automated Method. , 2017, 58, BIO168.		39
135	Systemic immunomodulatory strategies in high-risk corneal transplantation. Journal of Ophthalmic and Vision Research, 2017, 12, 81.	0.7	44
136	T Cellâ€“Derived Granulocyte-Macrophage Colony-Stimulating Factor Contributes to Dry Eye Disease Pathogenesis by Promoting CD11b+ Myeloid Cell Maturation and Migration. , 2017, 58, 1330.		27
137	Corneal Mesenchymal Stromal Cells Are Directly Antiangiogenic via PEDF and sFLT-1. , 2017, 58, 5507.		49
138	Evaluating Changes in Ocular Redness Using a Novel Automated Method. Translational Vision Science and Technology, 2017, 6, 13.	1.1	8
139	Scaling and maintenance of corneal thickness during aging. PLoS ONE, 2017, 12, e0185694.	1.1	16
140	Effect of Penetrating Keratoplasty and Keratoprosthesis Implantation on the Posterior Segment of the Eye. , 2016, 57, 1643.		18
141	Graft Site Microenvironment Determines Dendritic Cell Trafficking Through the CCR7-CCL19/21 Axis. , 2016, 57, 1457.		26
142	In Vivo Confocal Microscopy in Dry Eye Disease Associated With Chronic Graft-Versus-Host Disease. , 2016, 57, 4686.		39
143	E-Selectin Mediates Immune Cell Trafficking in Corneal Transplantation. Transplantation, 2016, 100, 772-780.	0.5	24
144	Overestimation of Corneal Endothelial Cell Density in Smaller Frame Sizes in In Vivo Confocal Microscopy. Cornea, 2016, 35, 363-369.	0.9	8

#	Article	IF	Citations
145	Impaired Function of Peripherally Induced Regulatory T Cells in Hosts at High Risk of Graft Rejection. Scientific Reports, 2016, 6, 39924.	1.6	38
146	Validity and Reliability of a Novel Ocular Pain Assessment Survey (OPAS) in Quantifying and Monitoring Corneal and Ocular Surface Pain. Ophthalmology, 2016, 123, 1458-1468.	2.5	70
147	A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease. Ophthalmology, 2016, 123, 1449-1457.	2.5	59
148	Alloimmunity and Tolerance in Corneal Transplantation. Journal of Immunology, 2016, 196, 3983-3991.	0.4	102
149	IL-17 Augments B Cell Activation in Ocular Surface Autoimmunity. Journal of Immunology, 2016, 197, 3464-3470.	0.4	52
150	In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2 Treatment Increases Allograft Survival in Corneal Transplantation. Transplantation, 2016, 100, 525-532.	0.5	65
151	Patients' Perspectives on Their Dry Eye Disease. Ocular Surface, 2016, 14, 440-446.	2.2	10
152	Ocular Manifestations of Inherited Phospholipase-CÎ³2â€“Associated Antibody Deficiency and Immune Dysregulation. Cornea, 2016, 35, 1656-1657.	0.9	9
153	Novel Insights Into the Immunoregulatory Function and Localization of Dendritic Cells. Cornea, 2016, 35, S49-S54.	0.9	29
154	Neuropeptide substance P and the immune response. Cellular and Molecular Life Sciences, 2016, 73, 4249-4264.	2.4	311
155	Prevalence of ocular hypertension and glaucoma in patients with chronic ocular graft-versus-host disease. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 923-928.	1.0	17
156	PTK7 ⁺ Mononuclear Cells Express VEGFR2 and Contribute to Vascular Stabilization by Upregulating Angiopoietin-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1606-1615.	1.1	10
157	Sufficient Evidence for Lymphatics in the Developing and Adult Human Choroid?. , 2015, 56, 6709.		18
158	Contralateral Clinically Unaffected Eyes of Patients With Unilateral Infectious Keratitis Demonstrate a Sympathetic Immune Response. , 2015, 56, 6612.		56
159	Involvement of Corneal Lymphangiogenesis in a Mouse Model of Allergic Eye Disease. , 2015, 56, 3140.		49
160	Corneal Epithelial Immune Dendritic Cell Alterations in Subtypes of Dry Eye Disease: A Pilot In Vivo Confocal Microscopic Study. , 2015, 56, 7179.		119
161	Effects of Corneal Nerve Density on the Response to Treatment in Dry Eye Disease. Ophthalmology, 2015, 122, 662-668.	2.5	87
162	Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 901-907.	1.0	17

#	Article	IF	Citations
163	Vision-Related Quality of Life in Patients with Ocular Graft-versus-Host Disease. Ophthalmology, 2015, 122, 1669-1674.	2.5	63
164	InÂVivo Confocal Microscopic Changes of the Corneal Epithelium and Stroma in Patients With Herpes Zoster Ophthalmicus. American Journal of Ophthalmology, 2015, 159, 1036-1044.e1.	1.7	16
165	Alteration of Galectin-3 in Tears of Patients With Dry Eye Disease. American Journal of Ophthalmology, 2015, 159, 1027-1035.e3.	1.7	41
166	Reduced Corneal Endothelial Cell Density inÂPatients With Dry Eye Disease. American Journal of Ophthalmology, 2015, 159, 1022-1026.e2.	1.7	49
167	Comparison of Two Questionnaires for Dry Eye Symptom Assessment. Ophthalmology, 2015, 122, 1498-1503.	2.5	120
168	Onset of Ocular Graft-Versus-Host Disease Symptoms After Allogeneic Hematopoietic Stem Cell Transplantation. Cornea, 2015, 34, 243-247.	0.9	55
169	VEGF-trap Aflibercept Significantly Improves Long-term Graft Survival in High-risk Corneal Transplantation. Transplantation, 2015, 99, 678-686.	0.5	64
170	Degeneration and Regeneration of Subbasal Corneal Nerves after Infectious Keratitis. Ophthalmology, 2015, 122, 2200-2209.	2.5	54
171	Corneal Inflammation After Miniature Keratoprosthesis Implantation. Investigative Ophthalmology and Visual Science, 2015, 56, 185-189.	3.3	22
172	Ocular surgical models for immune and angiogenic responses. Journal of Biological Methods, 2015, 2, e27.	1.0	29
173	Corneal Lymphatics: Role in Ocular Inflammation as Inducer and Responder of Adaptive Immunity. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	49
174	A Novel Murine Model for Keratoprosthesis. , 2014, 55, 3681.		9
175	Consensus Statement on the Immunohistochemical Detection of Ocular Lymphatic Vessels. , 2014, 55, 6440.		71
176	CCR7 Is Critical for the Induction and Maintenance of Th17 Immunity in Dry Eye Disease. , 2014, 55, 5871.		41
177	Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1755-1762.	1.0	28
178	Alkali Burn to the Eye. Cornea, 2014, 33, 382-389.	0.9	68
179	Extraorbital Lacrimal Gland Excision. Cornea, 2014, 33, 1336-1341.	0.9	56
180	Effects of Topical Janus Kinase Inhibition on Ocular Surface Inflammation and Immunity. Cornea, 2014, 33, 177-183.	0.9	28

#	Article	IF	Citations
181	CCL-21 Conditioned Regulatory T Cells Induce Allotolerance through Enhanced Homing to Lymphoid Tissue. Journal of Immunology, 2014, 192, 817-823.	0.4	43
182	What is the Value of Incorporating Tear Osmolarity Measurement in Assessing Patient Response to Therapy in Dry Eye Disease?. American Journal of Ophthalmology, 2014, 157, 69-77.e2.	1.7	63
183	Differentiation Potential of Limbal Fibroblasts and Bone Marrow Mesenchymal Stem Cells to Corneal Epithelial Cells. Stem Cells, 2014, 32, 717-729.	1.4	73
184	The Resolvin D1 Analogue Controls Maturation of Dendritic Cells and Suppresses Alloimmunity in Corneal Transplantation. , 2014, 55, 5944.		54
185	The Value of Tear Osmolarity as a Metric in Evaluating the Response to Dry Eye Therapy in the Clinic and in Clinical Trials. American Journal of Ophthalmology, 2014, 157, 915-916.	1.7	4
186	Ocular Graft-versus-Host Disease: A Review. Survey of Ophthalmology, 2013, 58, 233-251.	1.7	182
187	Corneal innervation as a window to peripheral neuropathies. Experimental Eye Research, 2013, 113, 148-150.	1.2	37
188	Effect of Desiccating Environmental Stress Versus Systemic Muscarinic AChR Blockade on Dry Eye Immunopathogenesis. , 2013, 54, 2457.		50
189	The CCR6/CCL20 Axis Mediates Th17 Cell Migration to the Ocular Surface in Dry Eye Disease. , 2013, 54, 4081.		59
190	On the Edge. JAMA Ophthalmology, 2013, 131, 1401.	1.4	11
191	Topical Interleukin 1 Receptor Antagonist for Treatment of Dry Eye Disease. JAMA Ophthalmology, 2013, 131, 715.	1.4	99
192	Nerves and Neovessels Inhibit Each Other in the Cornea. , 2013, 54, 813.		60
193	IL-1 receptor antagonist in the treatment of dry eye disease. Expert Review of Ophthalmology, 2013, 8, 581-586.	0.3	0
194	International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I). Scientific Reports, 2013, 3, 3419.	1.6	180
195	Topical Ranibizumab as a Treatment of Corneal Neovascularization. Cornea, 2013, 32, 992-997.	0.9	76
196	Bilateral corneal ulceration in ocular graft-versus-host disease. Clinical Ophthalmology, 2013, 7, 2153.	0.9	31
197	The Ocular Redness Index: A Novel Automated Method for Measuring Ocular Injection. , 2013, 54, 4821.		43
198	Expression of the chemokine decoy receptor D6 mediates dendritic cell function and promotes corneal allograft rejection. Molecular Vision, 2013, 19, 2517-25.	1.1	8

#	Article	IF	Citations
199	Blockade of Prolymphangiogenic Vascular Endothelial Growth Factor C in Dry Eye Disease. JAMA Ophthalmology, 2012, 130, 84.	2.6	65
200	Gamma-Irradiation Reduces the Allogenicity of Donor Corneas. , 2012, 53, 7151.		36
201	Dry Eye Disease. JAMA Ophthalmology, 2012, 130, 90.	2.6	464
202	Expression of Toll-Like Receptor 4 Contributes to Corneal Inflammation in Experimental Dry Eye Disease. , 2012, 53, 5632.		70
203	PDE4 Inhibition Suppresses IL-17â€“Associated Immunity in Dry Eye Disease. , 2012, 53, 3584.		27
204	Vascular Endothelial Growth Factor-C Promotes Alloimmunity by Amplifying Antigen-Presenting Cell Maturation and Lymphangiogenesis. , 2012, 53, 1244.		49
205	Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. British Journal of Ophthalmology, 2012, 96, 3-9.	2.1	75
206	b-FGF Induces Corneal Blood and Lymphatic Vessel Growth in a Spatially Distinct Pattern. Cornea, 2012, 31, 804-809.	0.9	19
207	Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin). Ocular Surface, 2012, 10, 67-83.	2.2	138
208	Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease. American Journal of Ophthalmology, 2012, 154, 63-71.	1.7	76
209	Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization. American Journal of Ophthalmology, 2012, 154, 940-948.e1.	1.7	44
210	Dependence of Corneal Stem/Progenitor Cells on Ocular Surface Innervation. , 2012, 53, 867.		116
211	Donor-derived, tolerogenic dendritic cells suppress immune rejection in the indirect allosensitization-dominant setting of corneal transplantation. Journal of Leukocyte Biology, 2012, 91, 621-627.	1.5	49
212	Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease. Progress in Retinal and Eye Research, 2012, 31, 271-285.	7.3	256
213	Inflammatory Corneal Neovascularization: Etiopathogenesis. Seminars in Ophthalmology, 2011, 26, 235-245.	0.8	64
214	A Novel Function for Programmed Death Ligand-1. American Journal of Pathology, 2011, 178, 1922-1929.	1.9	49
215	Characterization of Langerin-Expressing Dendritic Cell Subsets in the Normal Cornea. , 2011, 52, 4598.		85
216	Inflammation and the Nervous System: The Connection in the Cornea in Patients with Infectious Keratitis. , 2011, 52, 5136.		213

#	Article	IF	Citations
217	Therapeutic Efficacy of Topical Epigallocatechin Gallate in Murine Dry Eye. Cornea, 2011, 30, 1465-1472.	0.9	57
218	A novel pro-lymphangiogenic function for Th17/IL-17. Blood, 2011, 118, 4630-4634.	0.6	98
219	Flt-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7â€“dependent pathway. Blood, 2011, 117, 5762-5771.	0.6	63
220	Corneal Endothelial Cells Are Protected from Apoptosis by Gene Therapy. Human Gene Therapy, 2011, 22, 549-558.	1.4	33
221	Delayed Type Hypersensitivity in the Pathogenesis of Recurrent Herpes Stromal Keratitis. Seminars in Ophthalmology, 2011, 26, 246-250.	0.8	8
222	Corneal Penetration of Topical and Subconjunctival Bevacizumab. , 2011, 52, 8718.		111
223	Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. Journal of Experimental Medicine, 2011, 208, 1083-1092.	4.2	150
224	Relapsing Polychondritis: Systemic and Ocular Manifestations, Differential Diagnosis, Management, and Prognosis. Seminars in Ophthalmology, 2011, 26, 261-269.	0.8	53
225	Interferon-Î³-secreting NK cells promote induction of dry eye disease. Journal of Leukocyte Biology, 2011, 89, 965-972.	1.5	69
226	A Novel Mouse Model for Neurotrophic Keratopathy: Trigeminal Nerve Stereotactic Electrolysis through the Brain. , 2011, 52, 2532.		69
227	Keratoconjunctivitis Sicca Manifestations in Ocular Graft Versus Host Disease: Pathogenesis, Presentation, Prevention, and Treatment. Seminars in Ophthalmology, 2011, 26, 251-260.	0.8	29
228	The culture and transplantation of human limbal stem cells. Journal of Cellular Physiology, 2010, 225, 15-19.	2.0	53
229	Regulation of T-Cell Chemotaxis by Programmed Death-Ligand 1 (PD-L1) in Dry Eyeâ€“Associated Corneal Inflammation. , 2010, 51, 3418.		57
230	Effects of Topical and Subconjunctival Bevacizumab in High-Risk Corneal Transplant Survival. , 2010, 51, 2411.		79
231	Role of CCR7 in Facilitating Direct Allosensitization and Regulatory T-Cell Function in High-Risk Corneal Transplantation. , 2010, 51, 816.		24
232	Evidence of Corneal Lymphangiogenesis in Dry Eye Disease. JAMA Ophthalmology, 2010, 128, 819.	2.6	97
233	Thrombospondin-1 Derived from APCs Regulates Their Capacity for Allosensitization. Journal of Immunology, 2010, 185, 4691-4697.	0.4	44
234	Corneal Sensation and Subbasal Nerve Alterations in Patients with Herpes Simplex Keratitis. Ophthalmology, 2010, 117, 1930-1936.	2.5	252

#	Article	IF	Citations
235	Depletion of Passenger Leukocytes from Corneal Grafts: An Effective Means of Promoting Transplant Survival?. , 2009, 50, 3137.		22
236	Characterization of Effector T Cells in Dry Eye Disease. , 2009, 50, 3802.		130
237	Levels of Foxp3 in Regulatory T Cells Reflect Their Functional Status in Transplantation. Journal of Immunology, 2009, 182, 148-153.	0.4	238
238	Prevalence of Dry Eye Disease Among US Men. JAMA Ophthalmology, 2009, 127, 763.	2.6	483
239	Autoimmunity in Dry Eye Is Due to Resistance of Th17 to Treg Suppression. Journal of Immunology, 2009, 182, 1247-1252.	0.4	253
240	Anti-angiogenesis Effect of the Novel Anti-inflammatory and Pro-resolving Lipid Mediators. , 2009, 50, 4743.		137
241	Blocking the path of lymphatic vessels. Nature Medicine, 2009, 15, 993-994.	15.2	33
242	Corneal Lymphangiogenesis: Implications in Immunity. Seminars in Ophthalmology, 2009, 24, 135-138.	0.8	36
243	Topical Bevacizumab in the Treatment of Corneal Neovascularization. JAMA Ophthalmology, 2009, 127, 381.	2.6	182
244	Contribution of Macrophages to Angiogenesis Induced by Vascular Endothelial Growth Factor Receptor-3-Specific Ligands. American Journal of Pathology, 2009, 175, 1984-1992.	1.9	83
245	High-frequency Topical Cyclosporine 0.05% in the Treatment of Severe Dry Eye Refractory to Twice-daily Regimen. Cornea, 2009, 28, 1091-1096.	0.9	86
246	The Structure and Function of the Limbal Stem Cell and the Disease States Associated With Limbal Stem Cell Deficiency. International Ophthalmology Clinics, 2009, 49, 43-52.	0.3	44
247	Corneal Nerve Alterations in Dry Eye-associated Ocular Surface Disease. International Ophthalmology Clinics, 2009, 49, 11-20.	0.3	49
248	Differential Roles of Direct and Indirect Allorecognition Pathways in the Rejection of Skin and Corneal Transplants. Transplantation, 2009, 87, 16-23.	0.5	44
249	Amelioration of Murine Dry Eye Disease by Topical Antagonist to Chemokine Receptor 2. JAMA Ophthalmology, 2009, 127, 882.	2.6	69
250	Modulation of Integrin Î±4Î²1 (VLA-4) in Dry Eye Disease. JAMA Ophthalmology, 2008, 126, 1695.	2.6	52
251	Chimeric Solid Tissue Grafts Diminish Allospecific Immunity. FASEB Journal, 2008, 22, 862.17.	0.2	0
252	Impact of Dry Eye Syndrome on Vision-Related Quality of Life. American Journal of Ophthalmology, 2007, 143, 409-415.e2.	1.7	694

#	Article	IF	Citations
253	Mist Delivery of Eye Medication to the Anterior Segment. American Journal of Ophthalmology, 2007, 144, 137-139.	1.7	6
254	Development and Validation of a Short Global Dry Eye Symptom Index. Ocular Surface, 2007, 5, 50-57.	2.2	164
255	Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American) Tj ETQq1 1 0.784314 rgBT /Overlo 330-43.	1.4	41
256	Validation and Repeatability of a Short Questionnaire for Dry Eye Syndrome. American Journal of Ophthalmology, 2006, 142, 125-131.e2.	1.7	112
257	Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11405-11410.	3.3	242
258	Radiotherapy-Induced Ocular Surface Disease. Cornea, 2005, 24, 909-914.	0.9	48
259	Chronic Ocular Surface Disease after Allogeneic Bone Marrow Transplantation. Ocular Surface, 2005, 3, 203-210.	2.2	69
260	Corneal Antigen Presentation: Molecular Regulation and Functional Implications. Ocular Surface, 2005, 3, S-169-S-172.	2.2	17